Preclinical Characterization of DPI-4452: A <sup>68</sup>Ga/<sup>177</sup>Lu Theranostic Ligand for Carbonic Anhydrase IX.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38514083.
- Also identified by DOI 10.2967/jnumed.123.266309 and PMC identifier 11064828.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The membrane protein carbonic anhydrase IX (CAIX) is highly expressed in many hypoxic or von Hippel-Lindau tumor suppressor-mutated tumor types. Its restricted expression in healthy tissues makes CAIX an attractive diagnostic and therapeutic target. DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, allowing radionuclide chelation for theranostic purposes. Here, we report CAIX expression in multiple tumor types and provide in vitro and in vivo evaluations of <sup>68</sup>Ga-labeled DPI-4452 ([<sup>68</sup>Ga]Ga-DPI-4452) and <sup>177</sup>Lu-labeled DPI-4452 ([<sup>177</sup>Lu]Lu-DPI-4452). <b>Methods:</b> CAIX expression was assessed by immunohistochemistry with a panel of tumor and healthy tissues. The molecular interactions of complexed and uncomplexed DPI-4452 with CAIX were assessed by surface plasmon resonance and cell-binding assays. In vivo characterization of radiolabeled and nonradiolabeled DPI-4452 was performed in HT-29 colorectal cancer (CRC) and SK-RC-52 clear cell renal cell carcinoma (ccRCC) human xenograft mouse models and in healthy beagle dogs. <b>Results:</b> Overexpression of CAIX was shown in several tumor types, including ccRCC, CRC, and pancreatic ductal adenocarcinoma. DPI-4452 specifically and selectively bound CAIX with subnanomolar affinity. In cell-binding assays, DPI-4452 displayed comparably high affinities for human and canine CAIX but a much lower affinity for murine CAIX, demonstrating that the dog is a relevant species for biodistribution studies. DPI-4452 was rapidly eliminated from the systemic circulation of beagle dogs. The highest uptake of [<sup>68</sup>Ga]Ga-DPI-4452 and [<sup>177</sup>Lu]Lu-DPI-4452 was observed in the small intestine and stomach, 2 organs known to express CAIX. Uptake in other organs (e.g., kidneys) was remarkably low. In HT-29 and SK-RC-52 xenograft mouse models, both [<sup>68</sup>Ga]Ga-DPI-4452 and [<sup>177</sup>Lu]Lu-DPI-4452 showed tumor-selective uptake; in addition, [<sup>177</sup>Lu]Lu-DPI-4452 significantly reduced tumor growth. These results demonstrated the theranostic potential of DPI-4452. <b>Conclusion:</b> DPI-4452 selectively targets CAIX. [<sup>68</sup>Ga]Ga-DPI-4452 and [<sup>177</sup>Lu]Lu-DPI-4452 localized to tumors and were well tolerated in mice. [<sup>177</sup>Lu]Lu-DPI-4452 demonstrated strong tumor growth inhibition in 2 xenograft mouse models. Thus, the 2 agents potentially provide a theranostic approach for selecting and treating patients with CAIX-expressing tumors such as ccRCC, CRC, and pancreatic ductal adenocarcinoma.
Medical subject headings
- Carbonic Anhydrase IX
- Radioisotopes
- Gallium Radioisotopes
- Lutetium